The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Letter to the Editor
I read the new drug comment on dust mite allergen extract for allergic rhinitis with interest.1 I am not sure why this product is being marketed or even discussed if the only benefit is a small reduction in symptoms but insufficient effect to reduce the use of rescue medications. The effect on IgE concentrations is interesting, but obviously fails to translate into clinically (and financially) relevant benefits. There are also unwelcome and possibly distressing adverse effects.
It will not be going into my armamentarium just yet, unless there is something of major importance I am missing. I think not.
Advocacy, continuing education and training